Node-positive Breast Cancer Clinical Trials

8 recruitingLast updated: June 17, 2026

There are 8 actively recruiting node-positive breast cancer clinical trials across 14 countries. Studies span Phase 2, Not Applicable, Phase 4. Top locations include Seoul, South Korea, Essen, Germany, Athens, Greece. Updated daily from ClinicalTrials.gov.


Node-positive Breast Cancer Trials at a Glance

8 actively recruiting trials for node-positive breast cancer are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Seoul, Essen, and Athens. Lead sponsors running node-positive breast cancer studies include Gangnam Severance Hospital, H. Lee Moffitt Cancer Center and Research Institute, and European Institute of Oncology.

Browse node-positive breast cancer trials by phase

About Node-positive Breast Cancer Clinical Trials

Looking for clinical trials for Node-positive Breast Cancer? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Node-positive Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Node-positive Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting

Audit of Targeted Sentinel Node Biopsy (TSNB) in Patients With Limited Nodal Disease Undergoing Primary Surgery

Breast CancerNode-positive Breast CancerSentinel Lymph Node Biopsy (SLNB)+4 more
University Hospitals of Derby and Burton NHS Foundation Trust300 enrolled12 locationsNCT07085442
Recruiting
Phase 2

Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer

Breast CancerNode-positive Breast CancerHER2-Negative Breast Carcinoma+1 more
UNC Lineberger Comprehensive Cancer Center32 enrolled1 locationNCT07276880
Recruiting
Phase 2

Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer

Breast CancerNode-positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute120 enrolled1 locationNCT06833502
Recruiting
Phase 2

Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer

Node-positive Breast Cancer
Washington University School of Medicine220 enrolled1 locationNCT06559540
Recruiting
Phase 4

OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk

Breast CancerNode-positive Breast CancerHER2-negative Breast Cancer+2 more
Gangnam Severance Hospital418 enrolled2 locationsNCT05333328
Recruiting
Not Applicable

Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS)

Node-positive Breast Cancer
University Hospital, Basel, Switzerland1,500 enrolled67 locationsNCT03513614
Recruiting
Not Applicable

Exploring the Tumor Micro-Environment with 68Ga-FAPi-46 PET/CT in Breast Cancer

Node-positive Breast CancerBreast Cancer Invasive
European Institute of Oncology92 enrolled1 locationNCT06790264
Recruiting

TAD in Primary Breast Cancer With Initially ≥ 3 Suspicious Lymph Nodes

Breast CancerNode-positive Breast Cancer
Kliniken Essen-Mitte150 enrolled1 locationNCT05462457